News
-
Regarding the NDA filing for YLB217, a biosimilar product of long-acting erythropoiesis stimulating agent NespⓇ ”read more” link to press release PDF.
-
< Caution Notice >
Recently, there was a case in which someone posted an advertisement for recruitment under our name on the recruitment page of one job advertising company and attempted to steal personal information. Such a case has nothing to do with us. We are currently not recruiting new employees including through such an advertising company.
-
Obtainment of Manufacturing and Sales Approval for Etanercept Biosimilar, Anti-rheumatoid Arthritis Agent ”read more” link to press release PDF.
-
Teijin, Yoshindo and YL Biologics Enter Into a Marketing Alliance Agreement for Etanercept Biosimilar, Anti-rheumatoid Arthritis Agent ”read more” link to press release PDF.
-
Pharmaceuticals and Medical Devices Agency accepts the filing for YLB113, a biosimilar product of anti-rheumatoid arthritis biopharmaceutical Enbrel® ”read more” link to press release PDF.
-
Lupin and Yoshindo’s JV - YL Biologics announces successful outcome of global Phase III study for Etanercept biosimilar in Rheumatoid Arthritis ”read more” link to press release PDF.
-
Execution of Technology Transfer Agreement and
Development Support Agreement for Development and Commercialization of a Biosimilar Product of Darbepoetin alfa ”read more” link to press release PDF.
-
YLB113 Phase3 Study launched
-
Toshihiko Hibino Assumed Presidency
-
YLB113 Phase1 Study Accomplished